Your browser doesn't support javascript.
COVID-19 Drug Repositioning: Present Status and Prospects
Studies in Systems, Decision and Control ; 366:645-671, 2022.
Article in English | Scopus | ID: covidwho-1516830
ABSTRACT
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing the COVID-19 disease has gained the status of a pandemic worldwide. Till now no appropriate drug has been identified which can become the gold standard for coronavirus-2 and drugs such as Favipiravir, Hydroxychloroquine and Remdesivir used for the treatment of severe cases of COVID-19 have not yielded satisfactory results owing to many side effects. Although the entire scientific fraternity of the world is currently engaged to find a permanent cure for this deadly disease, clinical development of a new drug or vaccine precisely for SARS-CoV-2 will normally take time. Given the pressing need to quickly find effectual medications for COVID-19, existing drugs are being repositioned. The term “repositioning” or “repurposing” refers to the use of approved drugs originally used against other pathogens which can also be used against SARS-CoV-2. These therapeutics can be chosen from a wide spectrum of drugs used for cancer-induced inflammation, immune dysfunction, and coagulopathy. As all these symptoms prevail in patients affected by COVID-19, it is reasonable to consider testing above mentioned agents in a rational manner against this viral illness. The main idea behind the repositioning of the drug is to lessen the time and expenditure which is done to find a new drug and then ushering its transition from bench to bedside. For narrowing down the search as to which therapeutics can be considered for repositioning, Artificial Intelligence (AI) can be of great aid. AI can quickly detect drugs that can fight against COVID-19 pandemic. Besides, it is a cheaper, faster, and effective approach to find repurposed drugs from a vast array of therapeutics thereby minimizing the failures in clinical trials. AI-based Deep learning models can also predict drug structures that could potentially treat COVID -19 which can be a step forward in finding appropriate drugs for COVID -19. The present book chapter will comprehensively highlight all these points. © 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG.

Full text: Available Collection: Databases of international organizations Database: Scopus Language: English Journal: Studies in Systems, Decision and Control Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: Scopus Language: English Journal: Studies in Systems, Decision and Control Year: 2022 Document Type: Article